Program Overview
Although bladder cancer is a heterogeneous collection of diseases, more than 90% of patients are diagnosed with its most common form, urothelial carcinoma, while the remaining 10% present with less prevalent phenotypes, including squamous, small cell and adenocarcinomas. Given the somewhat limited presentation of these other manifestations, this activity will focus almost exclusively on the current and future management of urothelial carcinoma, including a number of novel agents and strategies that have yielded favorable outcomes and led to a spate of FDA approvals.
Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Compare and contrast the available clinical trial evidence with the use of immune checkpoint inhibitors for the treatment of urothelial bladder carcinoma (UBC) to determine the current utility of these agents in clinical practice.
- Consider the recent FDA approval of pembrolizumab for high-risk, non-muscle-invasive UBC that is unresponsive to Bacillus Calmette-Guérin, and determine how this agent can be appropriately integrated into current care.
- Evaluate available data and ongoing trials investigating the use of anti-PD-1/PD-L1 antibodies as neoadjuvant or adjuvant therapy for muscle-invasive bladder cancer, and refer eligible patients for appropriate study participation.
- Review available clinical trial data leading to the recent FDA approval of the anti-PD-L1 antibody avelumab as maintenance therapy following response to first-line platinum-based chemotherapy for patients with metastatic UBC, and incorporate this novel treatment strategy into current management algorithms.
- Assess available and emerging clinical trial data evaluating the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with previously untreated metastatic UBC, and consider the potential role of this approach in routine practice.
- Recognize the FDA approval of erdafitinib for patients with advanced UBC and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
- Recall the mechanism of action and pivotal clinical trial findings with enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
- Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immunotherapeutic strategies for metastatic UBC, and counsel appropriately selected patients about participation in active research protocols.
Competencies to Be Addressed
Patient Care and Procedural Skills and Medical Knowledge
CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the conclusion of the activity.
Contact Information
If you have questions regarding credit, please contact cpdsupport@usf.edu, or call 813-224-7860.
Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.
Privacy Disclosure
Learners provide permission for USF Health to share their completion data with ACCME, who will transmit same on their behalf to ABIM.
Within 60 days of the end of the activity, USF Health will upload to ACCME the participant data of physicians who have met the ABIM MOC Points requirements; ACCME will transmit the same to ABIM.
Completion Requirements
Physicians seeking ABIM Points will be required to take an evaluation/post-test passing with a score of 80% or higher.
Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Equal Opportunity Statement
USF Health is an Equal Opportunity/Affirmative Action/Equal Access Institution.
Content Validation and Disclosures
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
Dr Balar —
Consulting Agreements: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics;
Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Immunomedics Inc, Janssen Biotech Inc, Merck, Nektar, Pfizer Inc, Seattle Genetics.
Prof Powles —
Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics;
Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Merck Serono, Merck Sharp & Dohme Corp, Novartis, Pfizer Inc, Roche Laboratories Inc, Seattle Genetics.
Dr Siefker-Radtke —
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Mirati Therapeutics, Nektar, Pfizer Inc, Seattle Genetics;
Contracted Research: Janssen Biotech Inc;
Speakers Bureau: Janssen Biotech Inc.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — No relevant conflicts to disclose.
Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seattle Genetics.